On November 9, 2026 Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced systemic treatments for cancers, reported a business update and announced results for the quarter ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have presented clinical data that demonstrated the potential of delivering alpha radiation via our proprietary targeted oncology platform," said Thijs Spoor, Perspective’s Chief Executive Officer. "With encouraging clinical findings observed to date that further support the best‑in‑class potential of bamzireotide, continued progress across two additional programs targeting melanoma and FAP-α-positive solid tumors, and investments in our manufacturing capabilities, we are well-positioned to lead the development of the field."

Recent Program Updates

Bamzireotide navoxetan (VMT-α-NET) in SSTR2-positive neuroendocrine tumors (NETs) and meningioma

Updated data were presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026 and the 2026 North American Neuroendocrine Tumors Society (NANETS) Multidisciplinary NET Medical Symposium showing strong clinical efficacy data. Read our complete NANETS press release here, and view our NANETS presentation on the Company’s website.

Enrollment in Cohort 4 has been completed. As of October 30, 2026, Cohort 4 of the dose-finding study for NETS closed for recruitment with 20 patients enrolled. The meningioma cohort remains open for recruitment with two patients treated as of October 30, 2026.

Pre-Phase 3 activities are progressing. We are targeting an end-of-Phase 2 meeting with the FDA in 1Q 2027.

European orphan medicinal product designation granted in July 2026 for the treatment of gastroenteropancreatic (GEP)-NETs.
Lapemelanotide zapixetar (VMT01) in MC1R-positive melanoma:

Data with longer follow-up were presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 41st Annual Meeting showing strong, durable disease control in heavily pre-treated patients. Read our complete SITC (Free SITC Whitepaper) press release here, and view our SITC (Free SITC Whitepaper) poster on the Company’s website.

Recruiting more patients to corroborate encouraging monotherapy findings. As of October 30, 2026, 12 patients have been treated in a monotherapy cohort allowing up to a cumulative 9 mCi (333 MBq), administered in three treatments of 3.0 mCi every eight weeks. Five patients have been treated since the cohort reopened during 3Q 2026; by mid-2027, they are expected to reach at least 24 weeks of follow-up. This cohort remains open for enrollment.
PSV359 in FAP-α-positive solid tumors

Study progressing. This dose-finding study progressed into the third dose cohort, with a cumulative dose of 24 mCi administered in up to four treatments every eight weeks during 2Q 2026; as of September 30, 2026, 17 patients had been treated across the three cohorts. The next clinical update is planned in 2027.

Fast Track designation granted. In October 2026, the FDA granted PSV359 Fast Track Designation for adult patients with locally advanced unresectable and/or metastatic fibroblast activation protein (FAP)-positive solitary fibrous tumors. In September 2026, we entered into a clinical trial collaboration and supply agreement with Merck to support potential evaluation of PSV359 in combination with Keytruda (pembrolizumab) for certain types of lung and colorectal cancers.
Manufacturing: We expect construction to be completed at the Chicago metro site in early 2027.

Third Quarter 2026 Financial Summary

Cash, cash equivalents, and short-term investments as of September 30, 2026, were approximately $202 million as compared to approximately $145 million as of December 31, 2025. We believe our cash, cash equivalents, and short-term investments are sufficient to fund our current planned clinical milestones and operational investments into 2028.

Research and development expenses were $26.1 million for the three months ended September 30, 2026, compared to $20.3 million for the three months ended September 30, 2025.

General and administrative expenses were $8.3 million for the three months ended September 30, 2026, compared to $7.7 million for the three months ended September 30, 2025.

Net loss for the three months ended September 30, 2026, was $32.4 million, or $0.27 per basic and diluted share, compared to a net loss of $26.0 million, or $0.35 per basic and diluted share, for the same period in 2025.

(Press release, Perspective Therapeutics, NOV 9, 2026, View Source [SID1234674518])

On November 9, 2026 Avanzanite Bioscience B.V. ("Avanzanite" or "Company") a European pharmaceutical company focused on rare diseases, reported an exclusive licence agreement with Montreal-based Cordex Biologics, an ExCellThera company ("ExCellThera"), a leader in enhanced blood stem cell therapies, to commercialise Zemcelpro. Zemcelpro received conditional marketing authorisation from the European Commission on 25 August 2025 for the treatment of adult patients with haematological malignancies requiring an allogeneic haematopoietic stem cell transplant (allo-HSCT) following myeloablative conditioning for whom no other type of suitable donor cells is available.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the agreement, Avanzanite will lead commercialisation across 32 countries including the European Economic Area, UK and Switzerland. Avanzanite will become the holder of the existing EU marketing authorisation for Zemcelpro and plans to submit marketing authorisation applications in the UK and Switzerland. ExCellThera will retain responsibility for manufacturing and supply and will continue to lead global development across potential indication expansion in specific patients.

Furthermore, Avanzanite will contribute to the cost of a planned Phase 3 trial evaluating Zemcelpro against haploidentical or mismatched unrelated donor transplantation in adult patients with high-and very high-risk acute leukaemias and myelodysplastic syndromes (MDS). The trial is intended to provide confirmatory evidence of efficacy and safety and may support a potential indication expansion.

"This partnership reflects why Avanzanite was founded: to unlock the full potential of innovative medicines for patients with rare diseases in Europe," said Adam Plich, Co-founder and CEO, Avanzanite Bioscience. "We believe that while discovering breakthrough medicines requires one kind of genius, ensuring those medicines reach patients who can benefit from them requires another. This partnership unites these strengths in a shared sense of purpose." Plich continues: "Our commitment also extends to supporting the funding of the planned Phase 3 trial to gather further evidence and explore the therapy’s potential for broader use."

Zemcelpro has orphan drug designation and was part of the European Medicines Agency’s PRIority MEdicines (PRIME) scheme during development. This scheme provides early and enhanced scientific and regulatory support for promising medicines addressing unmet medical needs.

"Our team and collaborators have worked relentlessly for many years to advance Zemcelpro from scientific discovery towards patient care," said David Millette, CEO of ExCellThera. "Avanzanite brings a pan-European footprint with deep expertise in rare disease launches and market access. We believe they are the ideal partner to help turn the promise of this science into impact for patients in need while allowing us to continue focusing on scientific and clinical development."

"For patients with blood cancers who require a donor stem cell transplant, finding suitable donor cells is a vital step in the treatment pathway," said Dr Jurjen Versluis, Internist-Haematologist, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. "When no other suitable donor cells are available, additional transplant options are important. Erasmus MC contributed to the clinical trials evaluating Zemcelpro, and we are pleased to have played a role in its clinical development."

The agreement advances Avanzanite’s ambition to become a European rare disease champion. With this fifth rare disease launch in four years, Zemcelpro extends the company’s haematology portfolio into stem cell therapy and haemato-oncology, alongside its ophthalmology and nephrology franchises. Founded in 2022, Avanzanite now has more than 110 employees across Europe and serves more than 400 patients.

About Zemcelpro

Zemcelpro is an allogeneic haematopoietic stem cell therapy authorised as a medicinal product in the European Union for use in eligible adults requiring allogeneic haematopoietic stem cell transplantation (allo-HSCT). It is made specifically for each patient from a single umbilical cord blood unit and contains two components: expanded CD34+ haematopoietic stem cells using proprietary UM171 technology (dorocubicel) and unexpanded CD34–cells. Following infusion, the CD34+ stem cells travel to the bone marrow where they divide and mature into specialised blood and immune cells. The unexpanded CD34–cells, consisting primarily of CD3+ T cells, play a complementary role by supporting immune reconstitution and providing graft-versus-leukaemia effects post-transplantation.

About Allogeneic Stem Cell Transplantation

Each year around 15,000 adults in the licensed territories require allogeneic haematopoietic stem cell transplantation (HSCT) as a potentially curative treatment for blood cancers such as acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), myelodysplastic syndromes (MDS), lymphoma and other diseases. However, one third of these patients urgently need a transplant but have no matched related donor. Most receive transplants from haploidentical or mismatched unrelated donors, which have an increased risk of serious complications, including graft-versus-host disease (GVHD) and infections, contributing to non-relapse mortality. Some are unable to receive a transplant at all and face the risk of relapse with little prospect of survival.

(Press release, ExCellThera, NOV 9, 2026, View Source [SID1234674517])

On November 9, 2026 Inocras Inc., a bioinformatics-led company harnessing the power of whole-genome data and proprietary analytics to deliver curated insights, reported that it will present the first public results from its multimodal agentic AI framework for automating variant curation and clinical interpretation of cancer whole-genome sequencing (WGS) analysis at the Association for Molecular Pathology (AMP) 2026 Annual Meeting & Expo, taking place November 10–14 in Seattle.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Developed to address a key scalability bottleneck in clinical Cancer WGS analysis, the AI framework is a preview of Inocras’s CancerVision workflow innovation. In its latest evaluation, the framework achieved 99.5% agreement with expert curation among accepted calls, while deferring 10.2% of candidate variants for expert review. It also demonstrated 98.4% reproducibility across all candidate variants in repeated analyses with identical inputs and settings and is projected to reduce expert review time by more than half.

"Whole-genome sequencing offers a comprehensive view of cancer genomes, but interpreting the volume of data can be challenging," said Jehee Suh, CEO of Inocras. "Our AI framework aims to streamline this process, making WGS more practical for clinical use by reducing curation workload while maintaining expert oversight."

Unlike approaches based primarily on genomic annotations, Inocras’s new AI framework combines multiple types of evidence that expert curators traditionally assess. The agent can perform a structured review of candidate driver variants using genomic annotations and sequencing metrics and, when additional evidence is needed, can visually inspect sequencing read alignments and retrieve internal knowledge base, expert-curated historical cases.

Inocras is continuing to accumulate additional real-world performance evidence while continuously refining the agent through expert feedback. Human experts retain responsibility for the review and sign-off on all clinical reports.

"Variant curation is becoming an increasingly important rate-limiting step as WGS moves toward broader clinical adoption," said WonChul Lee, CIO and Head of the Innovation Lab at Inocras. "By combining multimodal reasoning, historical expert knowledge, and continuous feedback, our AI framework will be able to automate routine decisions while directing expert attention to the cases that require it most."

Inocras’s AMP presentation, "A Multimodal Agentic AI Framework for Scalable Variant Curation and Clinical Interpretation of Cancer Whole-Genome Sequencing," will be presented by Hansol Park of Inocras’s Data-Centric AI team.

Oral Presentation

Session: Platform Presentations of Selected Informatics Abstracts I
Date: Thursday, November 12, 2026
Time: 2:30–2:45 PM
Presentation: I024 — A Multimodal Agentic AI Framework for Scalable Variant Curation and Clinical Interpretation of Cancer Whole-Genome Sequencing
Location: Room 608–609, Level 6, Arch Building, Seattle Convention Center, 705 Pike St., Seattle, WA
Poster Presentation

Poster Number: I024
Abstract Number: 2465932
Category: Informatics
Poster Display Dates: November 12–14, 2026
Presentation Date: Friday, November 13, 2026
Presentation Time: 9:15–10:15 AM
Location: Expo Hall, Seattle Convention Center

(Press release, Inocras, NOV 9, 2026, View Source [SID1234674516])

On November 9, 2026 Novocure (Nasdaq: NVCR) reported that it has received a Not Approvable Letter from the U.S. Food and Drug Administration (FDA) in response to its Premarket Approval (PMA) application for Optune Mya for the treatment of adult patients with brain metastases from non-small cell lung cancer following stereotactic radiation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Not Approvable Letter indicates that the FDA determined that uncertainty around the degree of clinical benefit provided by Optune Mya prevented approval of the PMA application. The FDA did not raise concerns related to the safety profile of Optune Mya. Novocure is evaluating the feedback and plans to meet with the FDA to determine if there are any options that would support approval of the PMA application that would not require additional clinical studies. There can be no assurance that these discussions or any future submissions regarding this PMA application will lead to an approval.

(Press release, NovoCure, NOV 9, 2026, View Source [SID1234674515])

On November 9, 2026 Qureator, a leading techbio company delivering regulatory-grade translational data through its vTIME 3D human tissue platform, reported preclinical data evaluating the dual pharmacology of a PD-1xVEGF bispecific antibody and the vascular safety profile of a T-cell engager in a poster at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 41st Annual Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Developing effective cancer therapies requires a deeper understanding of how treatments interact with the complex tumor microenvironment, yet traditional preclinical models often fall short of capturing these critical interactions," said Kyu Baek, Ph.D., chief executive officer of Qureator. "These findings highlight the unique capabilities of our AI-powered vTIME model to simultaneously evaluate vascular and immune responses within a fully human, patient-relevant system, while capturing translational safety and efficacy benchmarks. By providing a more comprehensive understanding of how cancer therapies behave in human tissue systems, we believe our vTIME platform has the potential to bridge critical gaps in preclinical research, reduce development risks, and ultimately accelerate the delivery of more effective treatments to patients."

Junfeng Wang, M.D., Ph.D., principal scientist and presenter of the poster, added, "We specifically tested our model with two of the most promising modalities in oncology, PD-1xVEGF bispecific antibodies and T-cell engagers. We were pleased to find the results provide clear mechanistic validation of its impact on human tumor cells, immune cells, and perfused human vessels, with particular insights into the therapeutic window between efficacy and CRS. The findings support vTIME as a physiologically relevant human tumor model for immune-oncology, which we believe provides essential translational insights to optimize therapeutic dosing and reduce clinical risk."

To address the translational gap that exists in oncology drug discovery and development today, Qureator developed vTIME, which incorporates perfusable blood vessels, stromal cells, and patient-derived cancer organoids that preserve tumor heterogeneity and genetic mutations. New data presented demonstrate the model’s ability to simultaneously evaluate vascular and immune responses to therapeutic interventions, including dose-dependent changes in vessel pruning, endothelial activation, T-cell infiltration, and anti-tumor immunity. Additionally, the model resolved distinct biphasic cytokine dynamics (IFN- and IL-6) and endothelial damage associated with CRS (Cytokine Release Syndrome), while demonstrating that co-administration of anti-IL-6R protected the microvasculature without blunting anti-tumor cytotoxicity. Together, these findings support the potential of the platform to provide a more physiologically relevant approach to preclinical oncology research, helping to inform therapeutic development and reduce translational risks.

All posters are available on the SITC (Free SITC Whitepaper) virtual meeting platform.

(Press release, Qureator, NOV 9, 2026, View Source [SID1234674514])